Top Story Today
Pelacarsen Destroyed a Dangerous Biomarker. Hearts Kept Failing Anyway.
Novartis and Ionis' pelacarsen substantially lowered lipoprotein(a) levels in an 8,323-patient trial, then completely failed to reduce heart attacks, strokes, or cardiovascular deaths. The Lp(a)HORIZON trial was supposed to validate a thesis that dozens of genetic studies supported: that lowering this inherited risk factor would save lives. It didn't. Both companies' shares dropped sharply, and the shockwave extends well beyond one drug. Amgen's olpasiran and Eli Lilly's oral candidate muvalaplin are chasing the same target, and every one of those programs now faces an existential question about whether lowering Lp(a) matters at all.
Why it matters: This isn't just one failed drug; it's a failed hypothesis test. The entire Lp(a)-lowering class, pursued by multiple billion-dollar pharma companies, now rests on shaky scientific ground, and the billion-dollar lesson reinforces drug development's oldest trap: crushing a biomarker is not the same as curing a disease.
Read more →Clinical Wins
The First Drug That Might Let Celiac Patients Eat Bread
Zero targeted therapies have ever been approved for celiac disease. Teva's TEV-53408 just cut gluten-induced intestinal damage roughly in half in a 50-patient Phase 2a trial, with immune cell infiltration barely budging in the treatment group compared to a surge on placebo. The drug blocks IL-15, the alarm bell that rallies the immune system against gluten. With 30-plus competitors still mostly in early stages and the last major Phase 3 attempt ending in futility, this is the cleanest win the celiac field has produced.
Read more →A Lung Blood Pressure Drug Just Aced Two Trials in Lung Scarring
United Therapeutics' inhaled treprostinil hit its primary endpoint in both TETON Phase 3 trials for idiopathic pulmonary fibrosis, significantly slowing lung function decline versus placebo. The drug, already sold as Tyvaso for pulmonary hypertension, would become the first inhaled antifibrotic if approved. The FDA has already accepted the company's supplemental application, putting it ahead of a crowded field of pipeline programs chasing this deadly, hard-to-treat disease.
Read more →Market Moves
Lilly Slashes Zepbound Prices on Higher Doses With Cheaper Vials
Eli Lilly is now selling Zepbound's 7.5 mg and 10 mg doses as single-dose vials through LillyDirect, cutting monthly costs by hundreds of dollars compared to the autoinjector pen. The Self Pay Journey Program drops both to $449 per month. It's a calculated play: Zepbound already commands roughly 70% of branded obesity prescription share, but Novo's oral Wegovy and compounding pharmacies are closing in. Lilly would rather lead the pricing transition than have it imposed.
Read more →Corporate Shakeups
Novartis Closes a Basel Factory While Pouring $23B Into U.S. Sites
Novartis is cutting 130 jobs and shutting down its Kleinbasel biologics site by 2027, the latest in a series of facilities it has closed or exited since 2021. But this isn't downsizing; it's relocating. The company is simultaneously investing $23 billion to build or expand 10 U.S. facilities, aiming to produce 100% of key medicines domestically. Tariff pressures and a shifting product portfolio (toward radioligand and RNA therapies) are redrawing pharma's manufacturing map.
Read more →Invivyd Installs Its Board Chair as CEO Weeks Before Pivotal Data
Invivyd just made finance veteran Marc Elia its CEO, replacing prior leadership weeks before Phase 3 results for its next-gen COVID antibody VYD2311. Elia is a capital allocator, not a scientist, which could signal the board is preparing for a commercial phase. Or it could mean something less optimistic. The DECLARATION and LIBERTY trial readouts, expected within weeks, will determine which interpretation is correct.
Read more →